drugset / Trial / NCT01008280

Baclofen to Reduce Alcohol Use in Veterans With HCV

NCT01008280

Phase 4 Completed 180 enrolled VA Office of Research and Development
RandomizedParallel-groupTriple-blindTreatment

Summary

Hepatitis C (HCV) is the most common blood born virus in the United States, affecting 1.8% of the general population and more than 5% of Veterans using VA facilities. As Veterans with HCV have high rates of co-morbid alcohol use disorders that accelerate greatly the liver damage caused by HCV, a safe and effective treatment for alcohol use disorders is needed. Baclofen is a novel treatment for alcohol use disorders that has minimal effect on the liver and may represent a safe and efficacious treatment option for Veterans with HCV and co-morbid alcohol use disorders.

Timeline

Start
2010-10
Primary completion
2014-03
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Baclofen Small molecule 10 mg Oral